Sarah D Berry1, Vasan S Ramachandran, Peggy M Cawthon, Philimon Gona, Robert R McLean, L Adrienne Cupples, Douglas P Kiel. 1. Hebrew SeniorLife, Institute for Aging Research & Harvard Medical School, 1200 Centre Street, Boston, MA 02131. (SDB, RRM, DPK); Boston University School of Medicine, 671 Harrison Avenue, Harrison Court B06, Boston, MA 02118. (RSV, LAC); Boston University, Department of Mathematics and Statistics, 111 Cummington St., Boston, MA 02115 (PG); NHLBI Framingham Heart Study (PG); California Pacific Medical Center Research Institute, Suite 5700, 185 Berry Street, San Francisco, CA 94107. (PC).
Abstract
BACKGROUND: Procollagen type III N-terminal peptide (P3NP) is released during collagen synthesis in muscle. Increased circulating P3NP is a marker not only of muscle growth, but also of muscle repair and fibrosis. Thus, P3NP may be a potential biomarker for sarcopenia. OBJECTIVE: To determine the association between plasma P3NP and lean mass and strength. DESIGN SETTING AND PARTICIPANTS: A cross-sectional study of men and women from the Framingham Offspring Study. Participants included a convenience sample of 687 members with a measure of plasma P3NP and lean mass, and 806 members with P3NP and quadriceps strength assessment. MEASUREMENTS: Linear regression was used to estimate the association between total and appendicular lean mass and plasma P3NP, and quadriceps strength and P3NP. RESULTS: Mean age was 58 years. Median plasma P3NP was similar in men (3.4 mg/L), premenopausal women (3.1 mg/L), and postmenopausal women (3.0 mg/L). In adjusted models, higher P3NP was associated with a modest decrease in total and appendicular lean mass in postmenopausal women [β= -0.13 unit P3NP/kg total lean mass; p=0.003]. A similar trend was found among premenopausal women, although results were not statistically significant [β=-0.10 unit P3NP/kg total lean mass; p=0.41]. No association between P3NP and lean mass was observed in men. P3NP was not associated with strength in men or women. CONCLUSION: Our results suggest that plasma P3NP might be a useful biomarker of muscle mass in postmenopausal women if longitudinal studies demonstrate that it has adequate sensitivity and specificity to predict muscle loss.
BACKGROUND: Procollagen type III N-terminal peptide (P3NP) is released during collagen synthesis in muscle. Increased circulating P3NP is a marker not only of muscle growth, but also of muscle repair and fibrosis. Thus, P3NP may be a potential biomarker for sarcopenia. OBJECTIVE: To determine the association between plasma P3NP and lean mass and strength. DESIGN SETTING AND PARTICIPANTS: A cross-sectional study of men and women from the Framingham Offspring Study. Participants included a convenience sample of 687 members with a measure of plasma P3NP and lean mass, and 806 members with P3NP and quadriceps strength assessment. MEASUREMENTS: Linear regression was used to estimate the association between total and appendicular lean mass and plasma P3NP, and quadriceps strength and P3NP. RESULTS: Mean age was 58 years. Median plasma P3NP was similar in men (3.4 mg/L), premenopausal women (3.1 mg/L), and postmenopausal women (3.0 mg/L). In adjusted models, higher P3NP was associated with a modest decrease in total and appendicular lean mass in postmenopausal women [β= -0.13 unit P3NP/kg total lean mass; p=0.003]. A similar trend was found among premenopausal women, although results were not statistically significant [β=-0.10 unit P3NP/kg total lean mass; p=0.41]. No association between P3NP and lean mass was observed in men. P3NP was not associated with strength in men or women. CONCLUSION: Our results suggest that plasma P3NP might be a useful biomarker of muscle mass in postmenopausal women if longitudinal studies demonstrate that it has adequate sensitivity and specificity to predict muscle loss.
Entities:
Keywords:
P3NP; lean mass; procollagen type III N-telopeptide
Authors: Andréia Biolo; Luis E Rohde; Livia A Goldraich; Marcello Mascarenhas; Dora V Palombini; Nadine Clausell Journal: Biomarkers Date: 2009-09 Impact factor: 2.658
Authors: Shalender Bhasin; E Jiaxiu He; Miwa Kawakubo; E Todd Schroeder; Kevin Yarasheski; Gregory J Opiteck; Alise Reicin; Fabian Chen; Raymond Lam; Jeffrey A Tsou; Carmen Castaneda-Sceppa; Ellen F Binder; Stanley P Azen; Fred R Sattler Journal: J Clin Endocrinol Metab Date: 2009-10-16 Impact factor: 5.958
Authors: Ian Janssen; Richard N Baumgartner; Robert Ross; Irwin H Rosenberg; Ronenn Roubenoff Journal: Am J Epidemiol Date: 2004-02-15 Impact factor: 4.897
Authors: G Klappacher; P Franzen; D Haab; M Mehrabi; M Binder; K Plesch; R Pacher; M Grimm; I Pribill; H G Eichler Journal: Am J Cardiol Date: 1995-05-01 Impact factor: 2.778
Authors: Matteo Cesari; Roger A Fielding; Marco Pahor; Bret Goodpaster; Marc Hellerstein; Gabor A van Kan; Stefan D Anker; Seward Rutkove; J Willem Vrijbloed; Maria Isaac; Yves Rolland; Christine M'rini; Mylène Aubertin-Leheudre; Jesse M Cedarbaum; Mauro Zamboni; Cornell C Sieber; Didier Laurent; William J Evans; Ronenn Roubenoff; John E Morley; Bruno Vellas Journal: J Cachexia Sarcopenia Muscle Date: 2012-08-03 Impact factor: 12.910
Authors: Margaret M Band; Deepa Sumukadas; Allan D Struthers; Alison Avenell; Peter T Donnan; Paul R Kemp; Karen T Smith; Cheryl L Hume; Adrian Hapca; Miles D Witham Journal: Trials Date: 2018-01-04 Impact factor: 2.279